Johnson & Johnson $JNJ Shares Sold by Farmers Trust Co.

Key Points

• Farmers Trust Co. reduced its holdings in Johnson & Johnson by 6.3% during the 2nd quarter, selling 3,346 shares, which now make up 1.4% of its investment portfolio.
• Insider activity noted that EVP Jennifer L. Taubert sold 56,471 shares of J&J stock for over $10 million, resulting in a 24.08% decrease in her ownership position.
• Analysts have upgraded their price objectives for Johnson & Johnson, with Citigroup raising its target from $185 to $200, reflecting a consensus rating of "Moderate Buy" with a target price of $181.40.

Farmers Trust Co. lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 6.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 49,781 shares of the company's stock after selling 3,346 shares during the quarter. Johnson & Johnson comprises approximately 1.4% of Farmers Trust Co.'s investment portfolio, making the stock its 17th largest holding. Farmers Trust Co.'s holdings in Johnson & Johnson were worth $7,604,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Brighton Jones LLC increased its holdings in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the period. Capital A Wealth Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $50,000. LifeWealth Investments LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $226,000. Menard Financial Group LLC boosted its position in Johnson & Johnson by 11.1% in the 4th quarter. Menard Financial Group LLC now owns 1,866 shares of the company's stock worth $270,000 after purchasing an additional 187 shares in the last quarter. Finally, Total Wealth Planning & Management Inc. purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $628,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have commented on JNJ. The Goldman Sachs Group upped their price objective on Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a research report on Friday, September 19th. UBS Group upped their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Barclays increased their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Citigroup increased their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. Finally, Bank of America increased their target price on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $181.40.

Johnson & Johnson Trading Up 1.2%

Shares of JNJ stock opened at $176.35 on Wednesday. The stock's fifty day moving average is $173.56 and its two-hundred day moving average is $161.79. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market capitalization of $424.71 billion, a P/E ratio of 18.86, a PEG ratio of 2.22 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the firm posted $2.82 EPS. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.